Targeting Rho GTPase signaling for cancer therapy

Mardilovich, K., Olson, M.F. and Baugh, M. (2012) Targeting Rho GTPase signaling for cancer therapy. Future Oncology, 8(2), pp. 165-177. (doi: 10.2217/fon.11.143)

Full text not currently available from Enlighten.

Abstract

Accumulating evidence from basic and clinical studies supports the concept that signaling pathways downstream of Rho GTPases play important roles in tumor development and progression. As a result, there has been considerable interest in the possibility that specific proteins in these signal transduction pathways could be potential targets for cancer therapy. A number of inhibitors targeting critical effector proteins, activators or the Rho GTPases themselves, have been developed. We will review the strategies currently being used to develop inhibitors of Rho GTPases and downstream signaling kinases and discuss candidate entities. Although molecularly targeted drugs that inhibit Rho GTPase signaling have not yet been widely adopted for clinical use, their potential value as cancer therapeutics continues to drive considerable pharmaceutical research and development.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Baugh, Dr Mark and Mardilovich, Dr Katerina and Olson, Professor Michael
Authors: Mardilovich, K., Olson, M.F., and Baugh, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Future Oncology
ISSN:1479-6694

University Staff: Request a correction | Enlighten Editors: Update this record